NMRA•benzinga•
Neumora Therapeutics Q4 2024 GAAP EPS $(0.37) Beats $(0.45) Estimate, Cash Balance Of $307.6M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 3, 2025 by benzinga